Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 4/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.33 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23257662 | 0.84 | — | — | |
| SCHEMBL18181139 | 0.84 | EGLN1 (0.39) | EGLN1OPRL1CALCRL | |
| SCHEMBL23257568 | 0.83 | CALCRL (0.34) | EGLN1CALCRL | |
| SCHEMBL23257332 | 0.82 | — | — | |
| SCHEMBL23257628 | 0.82 | EGLN1 (0.34) | EGLN1CALCRL | |
| SCHEMBL23257421 | 0.82 | CALCRL (0.32) | CALCRL | |
| SCHEMBL23257603 | 0.80 | LMNA (0.35) | CALCRL | |
| SCHEMBL23257909 | 0.79 | POLB (0.34) | EGLN1CALCRL | |
| SCHEMBL15690620 | 0.78 | CALCRL (0.40) | EGLN1OPRL1CALCRL | |
| SCHEMBL30683634 | 0.78 | EGLN1 (0.37) | EGLN1OPRL1CALCRL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10221129-B2 | Inhibitors of human immunodeficiency virus replication | VIIV Healthcare UK (No.5) Limited (GB) | 2019-03-05 | — | — | US | disclosed |
| US-20180086697-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10221129-B2 | Inhibitors of human immunodeficiency virus replication | EIF2AK2, POLR2E, POLR2H | EGLN1 1850/4885OPRL1 4132/4885CALCRL 4539/4885 |
| US-20180086697-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | EIF2AK2, POLR2E, POLR2H | EGLN1 1850/4885OPRL1 4132/4885CALCRL 4539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.